Dynasty Wealth Management LLC Lowers Holdings in Novo Nordisk A/S (NYSE:NVO)

Dynasty Wealth Management LLC lowered its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 10.3% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 10,546 shares of the company’s stock after selling 1,214 shares during the period. Dynasty Wealth Management LLC’s holdings in Novo Nordisk A/S were worth $907,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Center for Financial Planning Inc. raised its position in Novo Nordisk A/S by 72.4% during the fourth quarter. Center for Financial Planning Inc. now owns 293 shares of the company’s stock valued at $25,000 after acquiring an additional 123 shares in the last quarter. Daiwa Securities Group Inc. purchased a new stake in Novo Nordisk A/S in the 3rd quarter worth approximately $28,000. Capital Performance Advisors LLP acquired a new stake in shares of Novo Nordisk A/S during the 3rd quarter worth approximately $42,000. Albion Financial Group UT increased its holdings in shares of Novo Nordisk A/S by 121.4% during the 4th quarter. Albion Financial Group UT now owns 507 shares of the company’s stock valued at $44,000 after purchasing an additional 278 shares in the last quarter. Finally, Sound Income Strategies LLC lifted its stake in shares of Novo Nordisk A/S by 82.1% in the 4th quarter. Sound Income Strategies LLC now owns 539 shares of the company’s stock valued at $46,000 after purchasing an additional 243 shares during the period. Institutional investors and hedge funds own 11.54% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently commented on NVO shares. BNP Paribas upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. Morgan Stanley started coverage on Novo Nordisk A/S in a research report on Wednesday, February 12th. They set an “equal weight” rating on the stock. UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. Finally, StockNews.com cut Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. Two investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Novo Nordisk A/S currently has an average rating of “Moderate Buy” and an average price target of $145.25.

Novo Nordisk A/S Stock Up 1.6 %

NVO opened at $90.68 on Friday. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62. Novo Nordisk A/S has a twelve month low of $77.82 and a twelve month high of $148.15. The company has a market cap of $406.91 billion, a PE ratio of 27.56, a price-to-earnings-growth ratio of 0.90 and a beta of 0.45. The company has a 50-day moving average price of $84.82 and a 200 day moving average price of $106.90.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. Sell-side analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The firm also recently announced a semi-annual dividend, which will be paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st will be paid a dividend of $0.7874 per share. This represents a yield of 1.2%. The ex-dividend date of this dividend is Monday, March 31st. This is a boost from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. Novo Nordisk A/S’s payout ratio is 47.72%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.